Key result
Antihypertensive treatment with low-dose thiazide diuretics did not increase the risk of new-onset type 2 diabetes compared to no diuretics (4.6% vs 4.9%; HR 0.93; 95% CI 0.55-1.58; p=0.800).
Why the study?
Does antihypertensive treatment with low-dose thiazide diuretics increase the risk of new onset type 2 diabetes in non-diabetic patients with essential hypertension?
RCT (n=1,130)
Unblinded with blinded assessment of endpoints
Randomized
Yes
Does antihypertensive treatment with low-dose thiazide diuretics increase the risk of new onset type 2 diabetes in non-diabetic patients with essential hypertension?
Hazard Ratio: 0.93 (95% CI 0.55–1.58)
Absolute Event Rate: 4.6% vs 4.9%
p-value: p=0.800
Low-dose thiazide diuretics do not increase the risk of new-onset type 2 diabetes in hypertensive patients compared to non-diuretic antihypertensive therapy.
Reassures on low-dose thiazide safety in non-diabetic hypertension; confirms metabolic neutrality versus other agents in RCT.
OBJECTIVES: Thiazide diuretics are one of the first choice antihypertensives but not optimally utilised because of concerns regarding their adverse effects on glucose metabolism. The Diuretics In the Management of Essential hypertension (DIME) study was designed, for the first time, to assess the risk for type 2 diabetes mellitus in patients with essential hypertension during antihypertensive treatment with low-dose thiazide diuretics compared to those not treated with diuretics. DESIGN: Multicentre, unblinded, pragmatic, randomised, controlled trial with blinded assessment of end points and intention-to-treat analysis that was started in 2004 and finished in 2012. SETTING: Hypertension clinics at 106 sites in Japan, including general practitioners' offices and teaching hospitals. PARTICIPANTS: Non-diabetic patients with essential hypertension. INTERVENTIONS: Antihypertensive treatment with low-dose thiazide diuretics at 12.5 mg/day of hydrochlorothiazide or equivalent (Diuretics group) or that without thiazide diuretics (No-diuretics group). MAIN OUTCOME: The primary outcome was new onset of type 2 diabetes diagnosed according to WHO criteria and the criteria of Japanese Society of Diabetes. RESULTS: 1130 patients were allocated to Diuretics (n=544) or No-diuretics group (n=586). Complete end point information was collected for 1049 participants after a median follow-up of 4.4 years. Diabetes developed in 25 (4.6%) participants in the Diuretics group, as compared with 29 (4.9%) in the No-diuretics group (HR 0.93; 95% CI 0.55 to 1.58; p=0.800). CONCLUSIONS: Antihypertensive treatment with thiazide diuretics at low doses may not be associated with an increased risk for new onset of type 2 diabetes. This result might suggest safety of use of low doses of thiazide diuretics. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT00131846.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2014) conducted an RCT in Essential hypertension (n=1,130). Low-dose thiazide diuretics vs. No thiazide diuretics was evaluated on New onset of type 2 diabetes (HR 0.93, 95% CI 0.55 to 1.58, p=0.800). Antihypertensive treatment with low-dose thiazide diuretics did not increase the risk of new-onset type 2 diabetes compared to no diuretics (4.6% vs 4.9%; HR 0.93; 95% CI 0.55-1.58; p=0.800).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: